著者

Jiawei Xu Xingyu Liu Shuqin Wu Deju Zhang Xiao Liu Panpan Xia Jitao Ling Kai Zheng Minxuan Xu Yunfeng Shen Jing Zhang Peng Yu

出版者

International Research and Cooperation Association for Bio & Socio-Sciences Advancement

雑誌

BioScience Trends (ISSN:18817815)

巻号頁・発行日

pp.2022.01473, (Released:2023-01-22)

参考文献数

149

被引用文献数

1

---

Metabolic-associated fatty liver disease (MAFLD) is the most common chronic liver disease globally and seriously increases the public health burden, affecting approximately one quarter of the world population. Recently, RNA binding proteins (RBPs)-related pathogenesis of MAFLD has received increasing attention. RBPs, vividly called the gate keepers of MAFLD, play an important role in the development of MAFLD through transcription regulation, alternative splicing, alternative polyadenylation, stability and subcellular localization. In this review, we describe the mechanisms of different RBPs in the occurrence and development of MAFLD, as well as list some drugs that can improve MAFLD by targeting RBPs. Considering the important role of RBPs in the development of MAFLD, elucidating the RNA regulatory networks involved in RBPs will facilitate the design of new drugs and biomarkers discovery.

著者

Xiang-Lin Chi Yong-Peng Yu Ke-Ping Bi

出版者

Japan Brain Science society

雑誌

脳科学誌 (ISSN:13415301)

巻号頁・発行日

vol.41, pp.17-36, 2013-09-30 (Released:2017-06-01)

---

The purpose of this study was to examine whether group intensive rehabilitation (GIR) can significantly improve lower limb functional outcome in patients early after stroke compared to routine rehabilitation (RR). Ninty-four patients were enrolled in this study who received GIR, individual intensive rehabilitation (IIR) or RR. Lower limb motor function was assessed using the Fugl-Meyer Assessment of Motor Recovery (FM). Dependence was recorded using the Modified Barthel Index (MBI), which is an index of daily living activities (ADL). Measures were taken before treatment and 3 weeks later respectively. Socioeconomics significance was assessed using rehabilitation cost-effectiveness ratio (CER). GIR and IIR produced greater gains than RR both in lower limb FM (p<0.01, p<0.01, respectively) and MBI (p=0.007, p=0.026, respectively) at 3 weeks after intervention. There were no significant differences both in FM and MBI score changes of lower limb between GIR and IIR (p=0.365, p=0.782, respectively). GIR had lower CER than IIR and RR (p<0.01, p<0.01, respectively). There were significant differences in CER between the three groups. Subjects in GIR had lower CER compared with those in IIR and RR (p<0.01, p<0.01, respectively). Patients receiving GIR or IIR could make greater gains than those receiving RR in lower limb motor function and ADL early after stroke, while there were no differences between those receiving GIR and IIR, which indicated that this beneficial effect was attributed to higher intensity of therapy, but had nothing to do with group factors. GIR may be a pragmatic, effective and economical method for patients early after stroke allowing for the optimal utilization of resources.

著者

Zhen-Guang Li Zhan-Cai Yu Yong-Peng Yu Dao-Zhen Wang Wei-Ping Ju Qi-Zhuan Wu

出版者

Japan Brain Science society

雑誌

脳科学誌 (ISSN:13415301)

巻号頁・発行日

vol.37, pp.35-46, 2011 (Released:2017-06-01)

参考文献数

32

---

Lysophosphatidic acid (LPA) is released from activated platelets. Statins are the commonly used anti-atherosclerotic drug. The purpose of this study is to observe whether atorvastatin could decrease the plasma LPA levels in ischemic stroke patients. A total of 386 subjects, including the 247 ischemic stroke cases and 139 healthy controls, were enrolled in this study. The 247 ischemic stroke cases were divided into Group A (n=109) and Group B (n=138) who had and had not received atorvastatin treatment before a stroke respectively. The plasma LPA levels of all the subjects were measured using chromatography. There was significant diffidence in the LPA levels between cases and controls (3.22±1.51μmol/L vs. 1.83±1.07μmol/L, p<0.01). The plasma LPA level in Group A was lower than that of Group B (2.66±1.23umol/L vs. 3.83±1.14umol/L, p<0.01). Atorvastatin (20mg/d) significantly reduced LPA levels in ischemic stroke patients (n=138) compared with that before atorvastatin administration (1.96±0.87μmol/L vs. 3.83±1.14μmol/L, p<0.01). However, the LPA levels re-elevated after atorvastatin withdrawl for one month. Atorvastatin could decrease the plasma LPA levels in patients with ischemic stroke, which providing a better understanding of how statins protect against ischemic stroke. It is plausible to speculate that statins might have an effect of anti platelet activation.